Abstract
We present a case of a patient with calcific mitral valve stenosis and plasmatic hypercoagulability. Using thrombelastography, the patient was determined to have an abnormally large velocity of plasma thrombus growth and strength with reduced vulnerability to lysis. Critically, increased carboxyhemoglobin concentration (2.4 %) was present, likely secondary to hemolysis from mitral stenosis and engagement of systemic heme oxygenase. It was determined that the patient’s plasmatic hypercoagulability was in part due to carboxyhemefibrinogen formation and iron-enhancement of coagulation via two thrombelastographic methods. In conclusion, future investigation of the involvement of both carbon monoxide and iron mediated hypercoagulability in the setting of stenotic valve disease is warranted.
References
Keenan NG, Cueff C, Cimadevilla C, Brochet E, Lepage L, Detaint D et al (2010) Usefulness of left atrial volume versus diameter to assess thromboembolic risk in mitral stenosis. Am J Cardiol 106:1152–1156
Varol E, Ozaydin M, Turker Y, Alaca S (2009) Mean platelet volume, an indicator of platelet activation, is increased in patients with mitral stenosis and sinus rhythm. Scand J Clin Lab Invest 69:708–712
Atalar E, Özmen F, Haznedaroglu I, Özer N, Aksöyek S, Övünç K, Nazlı N et al (2002) Impaired fibrinolytic capacity in rheumatic mitral stenosis with or without atrial fibrillation and nonrheumatic atrial fibrillation. Int J Hematol 76:192–195
Wallace HW, Kenepp DL, Blakemore WS (1970) Quantification of red blood cell destruction associated with valvular disease and prosthetic valves. J ThoracCardiovasc Surg 60:842–852
Matschke K, Schade I, Kappert U, Tugtekin SM, Schneider J, Jung F et al (2005) Lactate dehydrogenase (LDH) prior and post implantation of ATS® heart valves. Int J Cardiol 105:113–114
Nielsen VG, Pearson T, Smith MC (2013) Increased carbon monoxide production by hemeoxygenase-1 caused by device-mediated hemolysis: thrombotic phantom menace? Artif Organs 37:1008–1014
Landaw SA, Callahan EW, Schmid R (1970) Catabolism of heme in vivo: comparison of the simultaneous production of bilirubin and carbon monoxide. J Clin Invest 49:914–925
Nielsen VG, Kirklin JK, George JF (2009) Carbon monoxide releasing molecule-2 increases the velocity of thrombus growth and strength in human plasma. Blood Coagul Fibrinolysis 20:377–380
Nielsen VG, Kirklin JK, George JF (2009) Carbon monoxide releasing molecule-2 (CORM-2) decreases fibrinolysis in human plasma. Blood Coagul Fibrinolysis 20:448–455
Nielsen VG, Nfonsam VN, Matika RW, Ong ES, Jie T, Warneke JA, Steinbrenner EB (2014) Colon and pancreas tumors enhance plasma coagulation kinetics: role of hemeoxygenase-1. Blood Coagul Fibrinolysis 25:435–438
Nielsen VG, Pretorius E (2014) Iron enhanced coagulation is attenuated by chelation: a thrombelastographic and ultrastructural analysis. Blood Coagul Fibrinolysis (in press)
Nielsen VG, Pretorius E (2014) Iron and carbon monoxide enhance coagulation and attenuate fibrinolysis by different mechanisms. Blood Coagul Fibrinolysis (in press)
Wilks A, Heinzl G (2014) Heme oxygenation and the widening paradigm of heme degradation. Arch BiochemBiophys 544:87–95
Nielsen VG, Ley MLB, Waer AL, Alger PW, Matika RW, Steinbrenner EB (2013) Plasmatic hypercoagulation in patients with breast cancer: role of hemeoxygenase-1. Blood Coagul Fibrinolysis 24:809–813
Bundred NJ (2005) The effects of aromatase inhibitors on lipids and thrombosis. Br J Cancer 93(Suppl 1):S23–S27
Acknowledgments
This investigation was supported by the Department of Anesthesiology.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Thompson, J.L., Nielsen, V.G., Castro, A.R. et al. Heme oxygenase derived carbon monoxide and iron mediated plasmatic hypercoagulability in a patient with calcific mitral valve disease. J Thromb Thrombolysis 39, 532–535 (2015). https://doi.org/10.1007/s11239-014-1134-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-014-1134-x